Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1271-1277

  Kunze, Doreen ^a   Kraemer, Kai ^a   Erdmann, Kati ^a   Froehner, Michael ^a   Wirth, Manfred P ^a   Fuessel, Susanne ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Apoptosis; Combination therapy; RNA interference; SiRNA transfection; Small interfering RNA

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CELL COUNT; CELL VIABILITY; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, BCL-2; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84866484345     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1549     Document Type: Article

References (41)

1. Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289-293, 2009.
2. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
3. Herr HW, Dotan Z, Donat SM and Bajorin DF: Defining optimal therapy for muscle invasive bladder cancer. J Urol 177: 437-443, 2007.
4. Dogliotti L, Carteni G, Siena S, et al: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52: 134-141, 2007.
5. Burz C, Berindan-Neagoe I, Balacescu O and Irimie A: Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol 48: 811-821, 2009.
6. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
7. Brunelle JK and Letai A: Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122: 437-441, 2009.
8. Taylor RC, Cullen SP and Martin SJ: Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9: 231-241, 2008.
9. Glick SH, Howell LP and White RW: Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 155: 1754-1757, 1996.
10. Hussain SA, Ganesan R, Hiller L, et al: BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep 10: 571-576, 2003.
11. Ong F, Moonen LM, Gallee MP, et al: Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 61: 169-175, 2001.
12. Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF and McDonnell TJ: Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 3: 1823-1829, 1997.
13. Korkolopoulou P, Lazaris A, Konstantinidou AE, et al: Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol 41: 274-283, 2002.
14. Eckelman BP, Salvesen GS and Scott FL: Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7: 988-994, 2006.
15. Li M, Song T, Yin ZF and Na YQ: XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin Med J (Engl) 120: 469-473, 2007.
16. Velculescu VE, Madden SL, Zhang L, et al: Analysis of human transcriptomes. Nat Genet 23: 387-388, 1999.
17. Dohi T, Okada K, Xia F, et al: An IAP-IAP complex inhibits apoptosis. J Biol Chem 279: 34087-34090, 2004.
18. Margulis V, Lotan Y and Shariat SF: Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 26: 59-65, 2008.
19. Schultz IJ, Kiemeney LA, Witjes JA, et al: Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23: 3327-3331, 2003.
20. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI and Lotan Y: Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109: 1106-1113, 2007.
21. Weikert S, Christoph F, Schrader M, Krause H, Miller K and Muller M: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116: 100-104, 2005.
22. Dallas A and Vlassov AV: RNAi: a novel antisense technology and its therapeutic potential. Med Sci Monit 12: RA67-74, 2006.
23. Kim DH and Rossi JJ: Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184, 2007.
24. Han Z, Chatterjee D, Early J, Pantazis P, Hendrickson EA and Wyche JH: Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Res 56: 1621-1628, 1996.
25. Tan ML, Ooi JP, Ismail N, Moad AI and Muhammad TS: Programmed cell death pathways and current antitumor targets. Pharm Res 26: 1547-1560, 2009.
26. Hunter AM, LaCasse EC and Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12: 1543-1568, 2007.
27. Shangary S and Johnson DE: Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 17: 1470-1481, 2003.
28. Kunze D, Wuttig D, Fuessel S, et al: Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res 28: 2259-2263, 2008.
29. Ning S, Fuessel S, Kotzsch M, et al: siRNA-mediated downregulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25: 1065-1071, 2004.
30. Castanotto D, Sakurai K, Lingeman R, et al: Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res 35: 5154-5164, 2007.
31. Yang D, Song X, Zhang J, et al: Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim Biophys Sin (Shanghai) 42: 137-144, 2010.
32. Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA and Conti E: Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 131: 271-285, 2007.
33. Takizawa BT, Uchio EM, Cohen JJ, Wheeler MA and Weiss RM: Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. Cancer Invest 25: 678-684, 2007.
34. Sensintaffar J, Scott FL, Peach R and Hager JH: XIAP is not required for human tumor cell survival in the absence of an exogenous death signal. BMC Cancer 10: 11, 2010.
35. Anderson EM, Miller P, Ilsley D, et al: Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther 13: 406-414, 2006.
36. Gallardo-Perez JC, Espinosa M, Ceballos-Cancino G, et al: NF-kappa B is required for the development of tumor spheroids. J Cell Biochem 108: 169-180, 2009.
37. Yang TM, Barbone D, Fennell DA and Broaddus VC: Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol 41: 14-23, 2009.
38. Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K and Takei Y: Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125: 2978-2990, 2009.
39. Zhu H, Guo W, Zhang L, et al: Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther 4: 393-397, 2005.
40. Gill C, Dowling C, O'Neill AJ and Watson RW: Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer 8: 39, 2009.
41. Ruckert F, Samm N, Lehner AK, Saeger HD, Grutzmann R and Pilarsky C: Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. BMC Cancer 10: 379, 2010.